Point72 Asset Management L.P. lessened its stake in Vincerx Pharma, Inc. (NASDAQ:VINC – Free Report) by 29.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 674,193 shares of the company’s stock after selling 280,634 shares during the quarter. Point72 Asset Management L.P. owned about 2.27% of Vincerx Pharma worth $546,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Vincerx Pharma by 29.9% during the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock worth $3,375,000 after buying an additional 153,575 shares during the period. Marshall Wace LLP grew its stake in shares of Vincerx Pharma by 359.1% during the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after acquiring an additional 256,967 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Vincerx Pharma during the second quarter worth about $1,610,000. Institutional investors and hedge funds own 44.02% of the company’s stock.
Vincerx Pharma Stock Performance
Shares of VINC opened at $0.73 on Friday. Vincerx Pharma, Inc. has a one year low of $0.51 and a one year high of $9.37. The stock has a 50-day moving average price of $0.69 and a 200 day moving average price of $1.27. The company has a market capitalization of $21.66 million, a P/E ratio of -0.41 and a beta of 1.49.
About Vincerx Pharma
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
Recommended Stories
- Five stocks we like better than Vincerx Pharma
- The Significance of Brokerage Rankings in Stock Selection
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 9/30 – 10/4
- What is a Stock Market Index and How Do You Use Them?
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.